# Celea Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/celea-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.celeatx.com
- Total disclosed funding: $180M
- Latest round: Seed (Jul 2, 2026)
- Investors on record: 3

## About

Based in the US, Celea Therapeutics, Inc. is a biotechnology company specializing in innovative therapies for serious respiratory diseases, particularly idiopathic pulmonary fibrosis, through the development of advanced pharmaceutical solutions.

Celea Therapeutics, Inc. focuses on developing therapies for individuals with serious respiratory diseases, having been founded with a vision to address unmet medical needs and Sven Dethlefs is the Chief Executive Officer. The company is headquartered in Boston, US. Recently, on July 2, 2026, Celea Therapeutics raised USD 180.00 mn in a funding round led by Leaps by Bayer, PureTech Health plc, and RA Capital Management, bringing their total amount raised to USD 180.00 mn. This funding supports their development efforts, particularly for their lead product, deupirfenidone.

Celea Therapeutics is focused on developing innovative therapies for individuals suffering from serious respiratory diseases, with a particular emphasis on idiopathic pulmonary fibrosis (IPF). The company’s lead product, deupirfenidone, is an oral antifibrotic medication currently in Phase 3 clinical trials. Designed to be a next-generation treatment, deupirfenidone builds upon the established efficacy and safety profile of the FDA-approved drug pirfenidone, offering a modified approach that aims to reduce lung function decline. The company integrates the lived experiences of patients into its product development, ensuring that the therapies address significant unmet medical needs. Celea Therapeutics serves a global market, particularly targeting regions that include North America and Europe, where the burden of respiratory diseases is notably high.

Celea Therapeutics generates revenue through the development and eventual commercialization of its pharmaceutical products, particularly through the anticipated launch of deupirfenidone for IPF treatment. Revenue is structured around strategic partnerships with healthcare providers and potential collaborations with pharmaceutical distributors upon market entry. The business model is primarily B2B, focusing on agreements with hospitals, specialty pharmacies, and healthcare professionals who administer the medication to patients. Given the innovative nature of its product, Celea Therapeutics may explore pricing strategies that reflect the value of their proprietary treatments, particularly considering the urgent needs of patients with progressive fibrotic lung diseases. Detailed pricing structures for deupirfenidone and other potential offerings are tailored to align with market standards and reimbursement frameworks in various healthcare systems.

In July 2026, Celea Therapeutics, Inc. raised USD 180.00 mn in venture funding to support the initiation of its Phase 3 clinical trial for deupirfenidone and continue the development of the treatment for idiopathic pulmonary fibrosis. The company plans to leverage this funding to enhance their product pipeline and expand its geographical presence, particularly targeting new markets in North America and Europe by the end of 2027.

## Funding rounds

- Seed, Jul 2, 2026, $180M — RA Capital Management, PureTech Health plc, Leaps by Bayer

## Investors

- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Seed
- PureTech Health plc — Seed
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Seed